J. Molner AS Enters the US Market with Hydrocortisone Butyrate Lotion, 0.1%Tallinn, 2023-11-15 08:30 CET --
J. Molner AS (Nasdaq Tallinn: MOLNR) today announced its first product launch in the United States with its Hydrocortisone Butyrate Lotion, 0.1%. This launch represents a significant step in the company's strategy to develop a commercial platform for marketing its pharmaceutical products in international markets.
The Hydrocortisone Butyrate Lotion, 0.1%, now available in the US, is a topical treatment designed to alleviate inflammatory skin conditions. Detailed information about the product can be accessed through the DailyMed website at https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=160c463e-80d2-4bca-8b7f-42279617e309&version=3.
“Our entrance into the US market with the Hydrocortisone Butyrate Lotion, 0.1% is a measured step forward for J. Molner AS,” remarked Jason Grenfell-Gardner, Founder of J. Molner AS. “We look at this achievement as a direct result of our focus on meticulous planning and execution. It is a strong platform from which we will continue to deliver quality pharmaceuticals to meet patient needs globally.”
J. Molner AS remains focused on steady growth and the continued pursuit of excellence in pharmaceutical development.
For additional information about J. Molner AS, please visit www.jmolner.com.
For additional information please contact:
Jason Grenfell-Gardner
J. Molner AS
Management Board member
+372 536 00 346
jason@jmolner.com
|